These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 23538634)

  • 1. Subconjunctival bevacizumab injection for ocular surface squamous neoplasia.
    Faramarzi A; Feizi S
    Cornea; 2013 Jul; 32(7):998-1001. PubMed ID: 23538634
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of topical bevacizumab for conjunctival intraepithelial neoplasia.
    Özcan AA; Çiloğlu E; Esen E; Şimdivar GH
    Cornea; 2014 Nov; 33(11):1205-9. PubMed ID: 25014150
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Topical Bevacizumab for the Treatment of Ocular Surface Squamous Neoplasia.
    Asena L; Dursun Altınörs D
    J Ocul Pharmacol Ther; 2015 Oct; 31(8):487-90. PubMed ID: 26114378
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of subconjunctival bevacizumab on corneal neovascularization: results of a prospective study.
    Benayoun Y; Adenis JP; Casse G; Forte R; Robert PY
    Cornea; 2012 Aug; 31(8):937-44. PubMed ID: 22357391
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined use of subconjunctival and intracorneal bevacizumab injection for corneal neovascularization.
    Yeung SN; Lichtinger A; Kim P; Amiran MD; Slomovic AR
    Cornea; 2011 Oct; 30(10):1110-4. PubMed ID: 21673570
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Subconjunctival bevacizumab for corneal neovascularization.
    Zaki AA; Farid SF
    Acta Ophthalmol; 2010 Dec; 88(8):868-71. PubMed ID: 19519730
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinico-biochemical correlation of the effect of subconjunctival bevacizumab for corneal neovascularization.
    Agarwal S; Angayarkanni N; Iyer G; Srinivasan B; Natarajan R; Charola S; Arumugam S; Padmanabhan P
    Cornea; 2014 Oct; 33(10):1016-21. PubMed ID: 25090164
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Subconjunctival bevacizumab injection for corneal neovascularization.
    Bahar I; Kaiserman I; McAllum P; Rootman D; Slomovic A
    Cornea; 2008 Feb; 27(2):142-7. PubMed ID: 18216566
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Subconjunctival/perilesional recombinant interferon α2b for ocular surface squamous neoplasia: a 10-year review.
    Karp CL; Galor A; Chhabra S; Barnes SD; Alfonso EC
    Ophthalmology; 2010 Dec; 117(12):2241-6. PubMed ID: 20619462
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Subconjunctival bevacizumab for corneal neovascularization.
    Doctor PP; Bhat PV; Foster CS
    Cornea; 2008 Oct; 27(9):992-5. PubMed ID: 18812760
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficiency and safety of subconjunctival injection of anti-VEGF agent - bevacizumab - in treating dry eye.
    Jiang X; Lv H; Qiu W; Liu Z; Li X; Wang W
    Drug Des Devel Ther; 2015; 9():3043-50. PubMed ID: 26109847
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic effect of subconjunctival injection of bevacizumab in the treatment of corneal neovascularization.
    You IC; Kang IS; Lee SH; Yoon KC
    Acta Ophthalmol; 2009 Sep; 87(6):653-8. PubMed ID: 19021596
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Subconjunctival bevacizumab injection for corneal neovascularization in recurrent pterygium.
    Bahar I; Kaiserman I; McAllum P; Rootman D; Slomovic A
    Curr Eye Res; 2008 Jan; 33(1):23-8. PubMed ID: 18214740
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Subconjunctival injection of bevacizumab (avastin) on corneal neovascularization in different rabbit models of corneal angiogenesis.
    Chen WL; Lin CT; Lin NT; Tu IH; Li JW; Chow LP; Liu KR; Hu FR
    Invest Ophthalmol Vis Sci; 2009 Apr; 50(4):1659-65. PubMed ID: 18997093
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vivo corneal endothelial safety of intracameral bevacizumab and effect in neovascular glaucoma combined with Ahmed valve implantation.
    Shin JP; Lee JW; Sohn BJ; Kim HK; Kim SY
    J Glaucoma; 2009; 18(8):589-94. PubMed ID: 19826387
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized, controlled trial of conjunctival autografting combined with subconjunctival bevacizumab for primary pterygium treatment: 1-year follow-up.
    Nava-Castañeda A; Olvera-Morales O; Ramos-Castellon C; Garnica-Hayashi L; Garfias Y
    Clin Exp Ophthalmol; 2014 Apr; 42(3):235-41. PubMed ID: 23777441
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of subconjunctival and intraocular bevacizumab injections on corneal neovascularization in a mouse model.
    Avisar I; Weinberger D; Kremer I
    Curr Eye Res; 2010 Feb; 35(2):108-15. PubMed ID: 20136420
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Subconjunctival bevacizumab for corneal neovascularization].
    Gueudry J; Richez F; Tougeron-Brousseau B; Genevois O; Muraine M
    J Fr Ophtalmol; 2010 Nov; 33(9):630-6. PubMed ID: 21035899
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Topical and subconjunctival bevacizumab for corneal neovascularization in an experimental rat model.
    Öner V; Küçükerdönmez C; Akova YA; Çolak A; Karalezli A
    Ophthalmic Res; 2012; 48(3):118-23. PubMed ID: 22538642
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Refractory squamous cell carcinoma of the conjunctiva treated with subconjunctival ranibizumab (Lucentis): a two-year study.
    Finger PT; Chin KJ
    Ophthalmic Plast Reconstr Surg; 2012; 28(2):85-9. PubMed ID: 22186988
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.